Search Results
Jan 13, 2026, 04:15 ET ESTEVE übernimmt den Geschäftsbereich Infusion Specialty Therapies von TerSera Therapeutics und baut damit seine Präsenz in den USA aus
Therapiebereichen decken. Zusätzlich zu unserem innovativen Pharmageschäft bieten wir umfassende Auftragsfertigungs- und Entwicklungsdienstleistungen (CDMO) an und sind auf die Herstellung von pharmazeutischen Wirkstoffen (APIs) in unseren erstklassigen Produktionsstätten in Spanien, Mexiko, China und den
More news about: ESTEVE
Jan 13, 2026, 04:14 ET ESTEVE acquiert la division « Traitements injectables spécialisés » de TerSera Therapeutics pour renforcer sa présence aux États-Unis
activité pharmaceutique innovante, nous proposons des services complets de sous-traitance pharmaceutique (Contract Manufacturing and Development services, CDMO), et sommes spécialisés dans la production d'ingrédients pharmaceutiques actifs (IPA) grâce à des installations de classe mondiale en Espagne, au Mexique,
More news about: ESTEVE
Jan 13, 2026, 03:50 ET ESTEVE adquirirá la unidad de negocio de terapias especializadas de infusión de TerSera Therapeutics
diversas áreas terapéuticas. Además de nuestro innovador negocio farmacéutico, ofrecemos servicios integrales de Fabricación y Desarrollo por Contrato (CDMO), especializándonos en la producción de Ingredientes Farmacéuticos Activos (API) en instalaciones de primer nivel en España, México, China y Estados
More news about: ESTEVE
Jan 13, 2026, 03:45 ET ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence
several therapeutic areas. In addition, to our innovative pharma business, we offer comprehensive Contract Manufacturing and Development services (CDMO), specializing in the production of Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain, Mexico, China and the USA.ESTEVE's
More news about: ESTEVE
Jan 12, 2026, 11:00 ET TYBR Health Appoints Jeff Tyber to Board of Directors
Founder of Tyber Medical, which was acquired by Montagu and subsequently merged with Intech and Resolve Surgical to form Exalta Group, a leading MedTech CDMO+ organization for orthopedic companies. He currently serves as Group President and Board Member for Exalta. Previous roles include founding member of
More news about: TYBR Health
Jan 12, 2026, 09:00 ET Mandara Biopharma Files IND with the FDA to Advance Dronabinol Oral Solution Formulation for Alzheimer's Agitation
solution formulation was licensed from Benuvia Operations, LLC ("Benuvia"), a U.S.-based global Contract Development and Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) supplier servicing pharmaceutical and biotech companies. Under the agreement, Benuvia will serve as Mandara's
More news about: Mandara Biopharma Inc.
Jan 12, 2026, 08:00 ET Minaris and Genetix Biotherapeutics Expand Manufacturing Partnership to Support Commercial Supply for LYFGENIA™ (lovotibeglogene autotemcel)
Jan. 12, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, and Genetix Biotherapeutics Inc., a commercial-stage biotechnology company dedicated to delivering genetic
More news about: Minaris Advanced Therapies
Jan 12, 2026, 03:00 ET Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
more than 10 global pharmaceutical companies, Samil has established itself as a trusted partner in the global healthcare industry. Expanding into CMO/CDMO services in Ophthalmology field, Samil is seizing global opportunities with a state-of-the-art facility in Ho Chi Minh City, Vietnam, aimed at securing
More news about: Formosa Pharmaceuticals Inc.,
Jan 10, 2026, 13:43 ET Piramal Pharma ottiene un notevole aumento del punteggio nella valutazione della sostenibilità aziendale (CSA) a livello globale condotta da S&P nel 2025
(PPL), di cui fanno parte, tra altre imprese, sia Piramal Pharma Solutions – una delle principali organizzazioni di sviluppo e produzione su contratto (CDMO) a livello internazionale – sia Piramal Critical Care, ha ottenuto un punteggio di 63 nell'S&P Global CSA 2025, il che la posiziona nel 91o
More news about: Piramal Pharma Limited
Jan 10, 2026, 13:40 ET Piramal Pharma erzielt deutliche Punktzahlsteigerung bei der Bewertung der Unternehmensnachhaltigkeit (CSA) von S&P Global für 2025
Nachhaltigkeit.Piramal Pharma Limited (PPL), zu dem unter anderem Piramal Pharma Solutions – ein weltweit führendes Auftragsentwicklungs- und Produktionsunternehmen (CDMO) – und Piramal Critical Care gehören, erzielte im S&P Global CSA 2025 einen Wert von 63 und platzierte sich damit im 91. Perzentil der Pharmaindustrie.
More news about: Piramal Pharma Limited
Jan 10, 2026, 06:14 ET Piramal Pharma obtient une augmentation notable de son score lors de l'évaluation mondiale de la durabilité des entreprises (CSA) de 2025 de S&P
international.Piramal Pharma Limited (PPL), qui englobe, entre autres, Piramal Pharma Solutions - une organisation de développement et de fabrication sous contrat (CDMO) de premier plan au niveau mondial – et Piramal Critical Care, a obtenu une note de 63 sur le S&P Global CSA 2025, ce qui place la société dans
More news about: Piramal Pharma Limited
Jan 10, 2026, 06:11 ET Piramal Pharma logra un notable aumento de puntuación en la Evaluación S&P CSA 2025
Pharma Limited (PPL), que engloba, entre otras, a Piramal Pharma Solutions, una organización líder mundial en desarrollo y fabricación por contrato (CDMO), y a Piramal Critical Care, obtuvo una puntuación de 63 en el S&P Global CSA de 2025, lo que la sitúa en el percentil 91 de la industria farmacéutica.Esta
More news about: Piramal Pharma Limited
Jan 09, 2026, 15:49 ET Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Limited (PPL), which encompasses, inter alia, both Piramal Pharma Solutions – a leading global Contract Development and Manufacturing Organization (CDMO) – and Piramal Critical Care, earned a 63 on the 2025 S&P Global CSA, placing the Company in the 91st percentile within the pharmaceutical
More news about: Piramal Pharma Limited
Jan 09, 2026, 15:43 ET Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Limited (PPL), which encompasses, inter alia, both Piramal Pharma Solutions – a leading global Contract Development and Manufacturing Organization (CDMO) – and Piramal Critical Care, earned a 63 on the 2025 S&P Global CSA, placing the Company in the 91st percentile within the pharmaceutical
More news about: Piramal Pharma Limited
Jan 08, 2026, 11:39 ET Bionova Scientific and Syenex Forge Strategic Alliance to Expand Access to High-Quality Plasmid DNA for Advanced Therapies
2026 /PRNewswire/ -- Bionova Scientific LLC, an Asahi Kasei company and a bespoke contract development and manufacturing organization (CDMO), announced a strategic manufacturing alliance with Syenex, a genetic medicines platform company. This partnership will expand global access to
More news about: Bionova Scientific
Jan 08, 2026, 09:41 ET DCN Dx Announces Launch of New Prospective Biospecimen Collections Service
understand the specific operational challenges of IVD evidence generation. DCN Dx's biospecimens prospective collections integrate with their CRO and CDMO operations to keep studies, collections, and data management on the same track, or they can be contracted ad hoc."We built this because working
More news about: DCN Dx
Jan 07, 2026, 08:30 ET The Power of Less: Winning with Asset-Light Manufacturing, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how asset-light manufacturing accelerates market entry, increases flexibility and reduces risk through strategic CDMO partnerships. Attendees will gain insight into methods to redirect capital away from infrastructure and toward innovation, marketing and business expansion.
More news about: Xtalks
Jan 07, 2026, 08:30 ET Bridging Bench to Bedside: De‑Risking Biotherapeutic Administration via CDMO‑Led Clinical‑Mimic and In‑Use Testing Strategies, Upcoming Webinar Hosted by Xtalks
Bridging Bench to Bedside: De‑Risking Biotherapeutic Administration via CDMO‑Led Clinical‑Mimic and In‑Use Testing Strategies.ABOUT XTALKSXtalks, powered by Honeycomb Worldwide Inc., is a leading provider
More news about: Xtalks
Jan 07, 2026, 07:30 ET Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States
stem cell therapies; Made Scientific, Inc. (Made Scientific), a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO); and Zeo ScientifiX, Inc. (Zeo), a Florida-based clinical-stage biopharmaceutical company specializing in research, clinical trials, manufacturing and
More news about: Made Scientific, Inc.; Cytora
Jan 07, 2026, 07:00 ET Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
compliant with the continued listing requirements of Nasdaq; lower than anticipated revenues of Scinai's CDMO business in 2025 and thereafter, failure to sign agreements with other potential clients of the CDMO business; failure to receive grants under the EU STEP program or a delay in receiving grant decisions;
More news about: Scinai Immunotherapeutics Ltd.
Jan 07, 2026, 07:00 ET Xtalks Announces its Life Science Webinar Calendar for January 2026
Animal Rule in Drug Development with Modeling & SimulationJan 22 - Bridging Bench to Bedside: De-Risking Biotherapeutic Administration via CDMO-Led Clinical-Mimic and In-Use Testing StrategiesJan 28 - Detecting and Characterizing RNA Drug Candidates to Accelerate Therapeutic DevelopmentMEDICAL
More news about: Xtalks
Jan 07, 2026, 07:00 ET Genprex Provides Clinical Update on Diabetes Gene Therapy Program
have successfully executed our strategic plan to transfer production of GPX-002 to an experienced Contract Development and Manufacturing Organization (CDMO) and to submit a request to the FDA for a meeting regarding our Investigational New Drug (IND)-enabling studies, marking a pivotal step toward human
More news about: Genprex, Inc.
Jan 06, 2026, 20:16 ET 安立璽榮-KY 以免疫機制跳入白斑症藍海，跳脫受限單一疾病發展路徑創新局
Limited，本文簡稱「安立璽榮」）董事長陳泓愷、台杉投資生技基金（Taiwania Capital）執行合夥人黃立鑫，以及跨美日資金的 Axil Capital 執行合夥人 Frederick Shane 與基因線上共同探討安立璽榮一路以來的發展歷程。故事的核心主軸，圍繞創立初期即確立的免疫調節機制視角、優先鎖定白斑病的策略支持，同時借力日本兒科與罕見病專家、連結韓國 CDMO 產能進行跨境布局。安立璽榮的定位，不是「先選疾病種類」而是「先從機制下手」：以免疫調節作為共同的基礎，再推展至癌症、自體免疫與罕見發炎疾病等臨床領域應用。陳泓愷直言，團隊在公司成立之初即建立起系統性的評估流程——從疾病在生物學上是否站的住腳、臨床需求是否足夠、市場競爭到成功機率層
More news about: 基因線上
Jan 06, 2026, 08:34 ET GBI Biomanufacturing Announces the Appointment of Jesse McCool, Ph.D. as President
GBI Biomanufacturing, a U.S.-based biopharmaceutical CDMO providing integrated development and cGMP manufacturing services for complex biologics, today announced that Jesse McCool, Ph.D. has been appointed President.
More news about: GBI Biomanufacturing
Jan 06, 2026, 08:29 ET Terumo Launches SurTract™ Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR® Passive Safety Technology
Injection and Smart Protection in clinical environments. All products comply with ISO 11040-7 and ISO 23908 and are FDA 510(k)-cleared. As a trusted CDMO partner to global pharmaceutical and medical-device companies, Roncadelle integrates precision molding, automated assembly and packaging under cleanroom
More news about: Terumo Medical Corporation